Skip to main content

Adaptive Radiation for Abdominopelvic Metastases (ARAM) - Clinical Trial

Joshua Meyer, MD

Study Summary

Single arm Phase I trial of adaptive stereotactic body radiation (SBRT) for abdominopelvic metastases. Adaptive SBRT will allow for escalation of the prescription dose and target coverage while maintaining grade 3+ toxicity no greater than 10%. Subjects with metastatic cancer to the abdomen or pelvis requiring local control or palliation will be enrolled.

Protocol: 23-1012 / IRB23-1012
Phase: I
Investigator: Joshua Meyer, MD
Disease(s): Other Digestive Organ
Full Title: RT-218: Adaptive Radiation for Abdominopelvic Metastases (ARAM)

ClinicalTrials.gov
Visit ClinicalTrials.gov for a full clinical trial description.

Inclusion/Exclusion Criteria:

Contact Us
About This Trial:

For more information about this and other studies and to inquire about eligibility, please call 215-214-1515 or fill out this form.

  • Patients 18 or older with an ECOG of 0-1, that have a histologically or cytologically confirmed cancer that is metastatic (all solid tumor types accepted), with at least one target lesion untreated by radiation, IR techniques, or growing in the abdomen or pelvis. Adjacent lymph nodes in the same region (5 cm or closer) constitute one active lesion. Target lesion must be >10mm.
  • Must have normal organ and marrow function.
  • Previous systemic therapies are allowed, however subjects must not be receiving any chemotherapy, immunotherapy, radiotherapy, or other investigational agents.
  • Subjects must not have any radiographically visible peritoneal carcinomatosis or known active (untreated by RT) solid tumors outside of the abdomen/pelvis.
  • Must have less than 6 active metastatic sites.
  • Subjects must not have had prior radiotherapy to any target metastatic lesion.
  • Subjects must not have an uncontrolled intercurrent illness or any condition/significant co-morbidity that prevents safe delivery of SBRT.
  • Subjects must not be pregnant or breast feeding.
  •  

For more information about this and other studies and to inquire about eligibility, please call 215-214-1515.